Oral GLP‑1 hits Amazon

Amazon Pharmacy is now shipping the new oral Wegovy pill nationwide, putting the first FDA-approved weight-loss GLP-1 tablet into a major U.S. mail-order channel. (pharmaceuticalcommerce.com) Amazon Pharmacy said on January 12, 2026 that customers can get oral Wegovy through insurance or cash pay, with commercial patients paying as little as $25 a month and uninsured starting doses listed at $149 a month. The company said delivery is available in all 50 states, with same-day service for nearly half of U.S. customers. (pharmaceuticalcommerce.com) The Food and Drug Administration’s January 5, 2026 supplemental applications covered Wegovy tablets as well as Wegovy injection, and the agency’s approval letter said the updated labeling for both forms was effective on the date of the letter. Amazon’s pharmacy site now lists Wegovy tablets for prescription transfer. (accessdata.fda.gov, pharmacy.amazon.com) GLP-1 drugs copy a gut hormone that helps people feel fuller and lowers blood sugar; until now, most of the best-known obesity drugs in this class were weekly shots. A pill changes the routine from injection training and refrigeration questions to prescription, adherence, and side-effect questions that fit more easily into primary care and retail pharmacy workflows. (accessdata.fda.gov, pharmaceuticalcommerce.com) The oral market is getting crowded fast. Eli Lilly said in April 2025 that its once-daily experimental pill orforglipron cut A1C, a three-month blood sugar measure, by 1.3% to 1.6% and reduced weight by 16.0 pounds, or 7.9%, at the highest dose in a Phase 3 diabetes trial. (investor.lilly.com) Lilly reported again on February 26, 2026 that in a 1,698-patient head-to-head diabetes trial, orforglipron 36 mg lowered A1C by 2.2% versus 1.4% for oral semaglutide 14 mg and reduced weight by 19.7 pounds versus 11.0 pounds over 52 weeks. Lilly said it had already submitted orforglipron to regulators in more than 40 countries, with possible U.S. obesity action in the second quarter of 2026. (investor.lilly.com) Published obesity data have also moved beyond diabetes. A New England Journal of Medicine report on a 3,127-patient Phase 3 trial found 72 weeks of orforglipron led to average weight loss of 11.2% at the 36 mg dose versus 2.1% with placebo, with gastrointestinal side effects the most common reason patients stopped treatment. (nejm.org) Novo Nordisk is already widening the semaglutide lineup around the pill. Its U.S. news archive shows a lower U.S. list price announcement on February 24, 2026, a multi-month Wegovy subscription program on March 31, 2026, and nationwide availability for Wegovy HD injection on April 7, 2026. (novonordisk-us.com) That leaves doctors, insurers, and pharmacy benefit managers sorting through a bigger menu of semaglutide shots, semaglutide tablets, and Lilly’s pending oral rival. For patients, the first change is simpler: a weight-loss GLP-1 can now arrive in the mail as a pill instead of a pen. (pharmaceuticalcommerce.com, investor.lilly.com)